CHEK2-related cancer predisposition
MONDO:0700271Hereditary cancer predisposition due to variation(s) in the CHEK2 gene. Pathogenic germline variation in CHEK2 confers an autosomal dominant predisposition to tumor formation at multiple primary sites, including breast cancer and prostate cancer.
39 clinical trials for this condition and its sub-types, 7 tagged with CHEK2-related cancer predisposition itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
Promising prostate cancer trial for hispanic and black patients pulled before start
Disease control CancelledThis was a phase 2 trial testing a combination of niraparib and abiraterone plus prednisone for metastatic hormone-sensitive prostate cancer in Hispanic/Latino and Black patients with specific gene mutations. The study aimed to enroll 64 people but was withdrawn before any partic…
Phase 2 • Sponsor: Qian Qin • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Targeted drug olaparib tested in breast cancer patients with DNA repair flaws
Disease control OngoingThis phase 2 study tests the drug olaparib in 114 people with metastatic breast cancer whose tumors have mutations in certain DNA repair genes (like BRCA1, BRCA2, ATM, PALB2, and others). Olaparib is a PARP inhibitor that may kill cancer cells by blocking their ability to fix dam…
Phase 2 • Sponsor: Beth Israel Deaconess Medical Center • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC